Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
2.81 (1y: +2%)
Market Cap 215.92 M P/E(ttm)
Enterprise Value 260.45 M P/B 3.00
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.453
AMRS's Cash to Debt is ranked lower than
87% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. AMRS: 0.453 )
AMRS' s 10-Year Cash to Debt Range
Min: 0.45   Max: 20.49
Current: 0.45
0.45
20.49
Equity to Asset 0.239
AMRS's Equity to Asset is ranked lower than
74% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. AMRS: 0.239 )
AMRS' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.86
Current: 0.24
-0.93
0.86
F-Score: 2
Z-Score: -4.65
M-Score: 1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -273.90
AMRS's Operating margin (%) is ranked lower than
74% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. AMRS: -273.90 )
AMRS' s 10-Year Operating margin (%) Range
Min: -312.4   Max: -98.1
Current: -273.9
-312.4
-98.1
Net-margin (%) -278.4
AMRS's Net-margin (%) is ranked lower than
74% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. AMRS: -278.4 )
AMRS' s 10-Year Net-margin (%) Range
Min: -301.4   Max: -99.8
Current: -278.4
-301.4
-99.8
ROE (%) -305.7
AMRS's ROE (%) is ranked lower than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. AMRS: -305.7 )
AMRS' s 10-Year ROE (%) Range
Min: -305.7   Max: -26.6
Current: -305.7
-305.7
-26.6
ROA (%) -84.5
AMRS's ROA (%) is ranked lower than
90% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. AMRS: -84.5 )
AMRS' s 10-Year ROA (%) Range
Min: -84.5   Max: -22.9
Current: -84.5
-84.5
-22.9
ROC (Joel Greenblatt) (%) -143.30
AMRS's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMRS: -143.30 )
AMRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -188.3   Max: -115.3
Current: -143.3
-188.3
-115.3
» AMRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AMRS Guru Trades in Q2 2012

Paul Tudor Jones 11,300 sh (New)
Jim Simons 69,800 sh (New)
» More
Q3 2012

AMRS Guru Trades in Q3 2012

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2012

AMRS Guru Trades in Q4 2012

Paul Tudor Jones 20,600 sh (New)
» More
Q1 2013

AMRS Guru Trades in Q1 2013

Paul Tudor Jones 11,600 sh (-43.69%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRS



No Insider Trades Found!

Top Ranked Articles about Amyris, Inc.

Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Company
September 10, 2012
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Amyris Inc., AtriCure Inc., 3D Systems Corporation and Cooper Tire & Rubber Company Read more...

Ratios

vs
industry		 vs
history
P/B 3.00
AMRS's P/B is ranked higher than
59% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AMRS: 3.00 )
AMRS' s 10-Year P/B Range
Min: 0.6   Max: 5.37
Current: 3
0.6
5.37
P/S 3.37
AMRS's P/S is ranked higher than
73% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. AMRS: 3.37 )
AMRS' s 10-Year P/S Range
Min: 0.52   Max: 6.83
Current: 3.37
0.52
6.83
EV-to-EBIT 25.6
AMRS's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. AMRS: 25.6 )
AMRS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 25.6

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 35.1
AMRS's Price/Net Current Asset Value is ranked higher than
56% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. AMRS: 35.1 )
AMRS' s 10-Year Price/Net Current Asset Value Range
Min: 19.9   Max: 60.7
Current: 35.1
19.9
60.7
Price/Tangible Book 3.6
AMRS's Price/Tangible Book is ranked higher than
59% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. AMRS: 3.6 )
AMRS' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 3.4
Current: 3.6
1.3
3.4
Price/Median PS Value 1
AMRS's Price/Median PS Value is ranked higher than
53% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMRS: 1 )
AMRS' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.6
Current: 1
0.7
1.6

Business Description

Amyris, Inc. was formed as a California corporation in 2003 under the name Amyris Biotechnologies, Inc. The Company is building an integrated renewable products company to provide sustainable alternatives to a range of petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. It intend to commercialize these products as renewable ingredients in six target markets: cosmetics, lubricants, flavors and fragrances, polymers and plastic additives, home and personal care products, and transportation fuels. Its first technology success came through the development and application of its platform to create microbial strains that produce artemisinic acid, a precursor of artemisinin, an anti-malarial therapeutic. It granted a royalty-free license to this technology to Sanofi-Aventis, which currently expects to begin distributing artemisinin-based anti-malarial drugs made through its technology in 2012. It has two operating subsidiaries, Amyris Brasil Ltda. (formerly Amyris Brasil S.A.), or Amyris Brasil, and Amyris Fuels, LLC, or Amyris Fuels. Amyris Brasil oversees the establishment and expansion of Amyris's production in Brazil, and Amyris Fuels was established to help the Company develop fuel distribution capabilities in the U.S. Its production operations involve two steps. First, it produces the target molecule by means of an industrial fermentation process. In certain cases this target molecule is itself the desired end product. In other cases, it must be converted into the desired end product by means of chemical finishing steps. The Company is subject to a variety of federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the U.S., Brazil and other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:
Traded in other countries:3A0.Germany
» More Articles for AMRS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
Weekly CFO Sells Highlight: SCHW, TIBX, IL, AMRS, BCR, CCOI, CBST Apr 24 2011 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial